Granules India’s arm gets first USFDA approval for Hyderabad facility

11 Nov 2025 Evaluate

Granules India’s wholly owned subsidiary -- Granules Life Sciences (GLS) has received U.S. Food and Drug Administration (USFDA) approval for a product that was the subject of a Pre-Approval Inspection (PAI) conducted between July 28 and August 1, 2025.

There was one observation during that inspection, and the GLS had submitted its response within the stipulated time. With this approval, the GLS Hyderabad facility is now deemed approved by the U.S. FDA, marking a major milestone for Granules India as it expands its finished dosage manufacturing capabilities. This is the first USFDA approval for the GLS site. The company plans to launch the approved product in the U.S. market soon. The same product is already approved and manufactured at Granules’ Gagillapur facility. The new approval will help strengthen market share and support business continuity through multi-site manufacturing.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

560.65 -5.90 (-1.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×